Thermo Fisher Scientific (TMO)

Date: February 5, 2026 Introduction In the high-stakes world of life sciences, the "cold chain" is the invisible backbone of modern medicine. From the development of mRNA vaccines to the emerging frontiers of cell and gene therapy (CGT), the ability to store, manage, and analyze biological samples with absolute precision is no longer a luxury—it [...]

Thermo Fisher’s fourth quarter results exceeded Wall Street’s top-line and non-GAAP profit expectations, yet the market responded negatively, reflecting investor concerns beyond headline beats. Management highlighted robust growth in bioproduction, steady performance in clinical research, and continued momentum in pharma and biotech customer segments as key drivers. CEO Marc Casper attributed the quarter’s revenue strength to high-impact product launches—such as the Orbitrap Astro Zoom mass spectrometer and DynaDrive bioreactor—and the company’s ability to manage tariff headwinds and policy dynamics. He acknowledged that academic and industrial end markets remained pressured, particularly in the U.S. and China.

Life sciences company Thermo Fisher (NYSE:TMO) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 7.2% year on year to $12.22 billion. Its non-GAAP profit of $6.57 per share was 1.9% above analysts’ consensus estimates.

Thermo Fisher (TMO) Q4 2025 Earnings Transcript

Life sciences company Thermo Fisher (NYSE:TMO) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 7.2% year on year to $12.22 billion. Its non-GAAP profit of $6.57 per share was 1.9% above analysts’ consensus estimates.

Life sciences company Thermo Fisher (NYSE:TMO) will be reporting results this Thursday before market hours. Here’s what investors should know.

Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting bottom-line expectations for earnings per share, the healthcare giant reported a significant revenue miss that spooked investors, driven primarily by

The morning of January 20, 2026, 3M (NYSE: MMM) released its fourth-quarter and full-year 2025 financial results, signaling a definitive turn in the company’s multi-year effort to shed its image as a litigation-burdened conglomerate and re-emerge as a lean industrial powerhouse. The company reported adjusted earnings per share (EPS)

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

The traditional image of a scientist hunched over a microscope or mixing chemicals in a flask is being rapidly superseded by a new reality: the "Self-Driving Lab." Over the past several months, a revolutionary class of "Discovery AI" platforms has moved from theoretical pilots to active lab partners. These systems are no longer just processing [...]

As of January 2026, the landscape of biological research has been irrevocably altered by the maturation of AlphaFold 3, the latest generative AI milestone from Alphabet Inc. (NASDAQ: GOOGL). Developed by Google DeepMind and its drug-discovery arm, Isomorphic Labs, AlphaFold 3 has transitioned from a groundbreaking theoretical model into the foundational infrastructure of modern medicine. [...]

Date: January 14, 2026 Introduction Since its high-profile separation from industrial conglomerate 3M Company (NYSE: MMM) in April 2024, Solventum Corporation (NYSE: SOLV) has undergone a profound transformation. Once a steady but overshadowed healthcare division, Solventum has emerged as a focused, multi-billion-dollar medtech powerhouse. As of early 2026, the company is in the spotlight for [...]

In a move that signals the definitive convergence of high-performance computing and biotechnology, NVIDIA Corporation (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) announced a massive $1 billion "co-innovation" partnership at the J.P. Morgan Healthcare Conference on January 12, 2026. This five-year strategic alliance aims to re-engineer the

LANSING, MI – Shares of Neogen Corporation (NASDAQ: NEOG) experienced a dramatic surge in early trading today, climbing nearly 29% after the food and animal safety leader reported second-quarter fiscal 2026 financial results that blew past Wall Street expectations. The performance marks a definitive "return to growth" for the company, which

What a time it’s been for Thermo Fisher. In the past six months alone, the company’s stock price has increased by a massive 41.4%, reaching $591.90 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the research tools & consumables industry, including Thermo Fisher (NYSE:TMO) and its peers.

Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less room for explosive growth as scale works against them.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

New York, NY – December 9, 2025 – Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share. This declaration, coming on the heels of a consistently strong financial performance, reaffirms the company's